medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-16-88-90medsovet-2136Research ArticleАЛЛЕРГИЯALLERGYНОВЫЙ ОРИГИНАЛЬНЫЙ АНТИГИСТАМИННЫЙ ПРЕПАРАТ БИЛАСТИН В ЛЕЧЕНИИ АЛЛЕРГИЧЕСКОГО РИНИТАNEW ORIGINAL ANTIHISTAMINE BILASTINE IN THE TREATMENT OF ALLERGIC RHINITISКривопаловА. А.KrivopalovA. A.

Кандидат медицинских наук

PhD  in medicine

КоноплевО. И.KonoplevO. I.

Доктор медицинских наук,  профессор

MD, Prof.

ШервашидзеС. В.ShervashidzeS. V.ШаталовВ. А.ShatalovV. A.Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи Минздрава РоссииРоссияSaint-Petersburg Scientific and Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of RFRussian Federation2017081120170168890Copyright © Кривопалов А.А., Коноплев О.И., Шервашидзе С.В., Шаталов В.А., 20172017Кривопалов А.А., Коноплев О.И., Шервашидзе С.В., Шаталов В.А.Krivopalov A.A., Konoplev O.I., Shervashidze S.V., Shatalov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2136

Аллергический ринит – одно из наиболее широко распространенных заболеваний человека, связанное с серьезными ограничениями как в физических, психологических, так и в социальных аспектах жизни, являющееся причиной снижения качества жизни. Препаратами первого выбора у пациентов с симптомами сезонного и круглогодичного аллергического ринита как интермиттирующего, так и персистирующего течения являются антигистаминные препараты 2-го поколения, обладающие высоким сродством к Н1-рецепторам. В статье идет речь о новом представителе вышеуказанной группы лекарственных средств – оригинальном препарате Никсар® (биластин).

Allergic rhinitis is one of most widespread human diseases associated with severe limitations in physical, psychological, and social aspects of life, which is the reason for the decline in quality of life. The drugs of first choice in patients with symptoms of seasonal and perennial allergic rhinitis of intermittent as well as of persistent courses are antihistamines of 2nd generation with high affinity to H1-receptors. The article is about a new representative of the above group of drugs, the original drug Niksar® (bilastine).

аллергический ринитриноконъюнктивитантигистаминные препаратыНиксар® (биластин)allergic rhinitisrhinoconjunctivitisantihistaminesNixar® (bilastine)ReferencesLucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol, 2012, 35(suppl l): 18-24.Lucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol, 2012, 35(suppl l): 18-24.Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy, 2008, 63(Suppl. 86): 8-160.Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy, 2008, 63(Suppl. 86): 8-160.Василевский И.В. Реабилитация детей и подростков с заболеваниями органов дыхания, пищеварения, почек, сердечно-сосудистой системы и аллергическими болезнями в условиях поликлиники. Минск: БелМАПО, 2007: 157-171.Василевский И.В. Реабилитация детей и подростков с заболеваниями органов дыхания, пищеварения, почек, сердечно-сосудистой системы и аллергическими болезнями в условиях поликлиники. Минск: БелМАПО, 2007: 157-171.Горячкина Л.А., Кашкин Е.П., Терехова Е.П. и соавт. Клиническая аллергология и иммунология: руководство для практикующих врачей. Под ред. Л.А. Горячкиной и Е.П. Кашкина. М.: Миклош, 2009: 121.Горячкина Л.А., Кашкин Е.П., Терехова Е.П. и соавт. Клиническая аллергология и иммунология: руководство для практикующих врачей. Под ред. Л.А. Горячкиной и Е.П. Кашкина. М.: Миклош, 2009: 121.Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig, 2012, 32: 339-351.Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig, 2012, 32: 339-351.Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol, 1988, 94:187-191.Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol, 1988, 94:187-191.Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol, 1940, 30:121-145.Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol, 1940, 30:121-145.Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol, 1960, 151:416-435.Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol, 1960, 151:416-435.Sadaba B, Gomez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig, 2013, 33: 375-381.Sadaba B, Gomez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig, 2013, 33: 375-381.Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy, 2013, 68: 921-928.Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy, 2013, 68: 921-928.Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf, 2011, 10(5): 779-793.Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf, 2011, 10(5): 779-793.Corcostegui R, Labeaga L, Innerarity A, Berisa A, Oijales A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D, 2006,7: 219-231.Corcostegui R, Labeaga L, Innerarity A, Berisa A, Oijales A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D, 2006,7: 219-231.Sastre J, Mullol J, Valero A, Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin, 2012, 28: 121-130.Sastre J, Mullol J, Valero A, Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin, 2012, 28: 121-130.Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vslevocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, doubleblind, randomized, placebo-controlled study. Allergy, 2010, 65: 516-528.Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vslevocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, doubleblind, randomized, placebo-controlled study. Allergy, 2010, 65: 516-528.Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy, 2014, 4: 142-148.Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy, 2014, 4: 142-148.Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamineHI-receptor occupancy using 1 lC-doxepin positron emission tomography. JClinPharmacol,2004, 44: 890-900.Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamineHI-receptor occupancy using 1 lC-doxepin positron emission tomography. JClinPharmacol,2004, 44: 890-900.

The authors declare that there are no conflicts of interest present.